

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 982 035 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
01.03.2000 Bulletin 2000/09

(51) Int Cl.7: **A61K 38/13**, A61K 9/48,  
A61K 9/107, A61K 9/10

(21) Application number: **98306607.7**

(22) Date of filing: **18.08.1998**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **Panacea Biotech Limited**  
**New Delhi 110 001 (IN)**

(72) Inventors:  
• **Singh, Amarjit**  
**New Delhi 110001 (IN)**

• **Jain, Rajesh**  
**New Delhi 110001 (IN)**

(74) Representative: **Skalles, Humphrey John**  
**Frank B. Dehn & Co.,**  
**European Patent Attorneys,**  
**179 Queen Victoria Street**  
**London EC4V 4EL (GB)**

(54) **Cyclosporin composition comprising an hydrophilic carrier**

(57) A homogeneous substantially alcohol free, transparent solution of a cyclosporin which is clear, stable, flowable and easily measurable at a temperature of 15° to 45°C, which comprises a solution of a cyclosporin

in a hydrophilic carrier medium comprising (1) propylene glycol, (2) a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol, (3) a polyoxyethylene hydrogenated castor oil product and (4) triacetin.

**EP 0 982 035 A1**


## Description

[0001] The present invention relates to a novel homogeneous alcohol free, free flowing, clear and transparent pharmaceutical composition comprising a cyclosporin as active ingredient. The novel composition is characterised in having increased bioavailability when the drug is formulated in a solubilised system and also amenable to convenient commercial production.

## BACKGROUND OF THE INVENTION


[0002] Cyclosporins comprise a class of structurally distinctive, cyclic, poly-N-methylated endecapeptides, commonly possessing pharmacological, in particular immunosuppressive, anti-inflammatory and/or antiparasitic activity. The first of the cyclosporins to be isolated was the naturally occurring fungal metabolite ciclosporin or cyclosporine, also known as cyclosporin A and commercially available under several brands. ciclosporin is the cyclosporin of formula A:

(A)



wherein - MeBmt- represents the N-Methyl-(4R)-4-but-2E-en-1-yl-4-methyl-(L) threonyl residue of formula B.

(B)



in which -x-y- is --CH=CH-- (trans).

[0003] So far the primary area of clinical investigation for cyclosporin has been as an immunosuppressive agent, in particular in relation to its application to recipients of organ transplants, e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, bone-marrow, skin and corneal transplants and, in particular, allogenic organ transplants. In this field cyclosporin has achieved a remarkable success in its usage.

[0004] At the same time, applicability of cyclosporin to various autoimmune diseases and to inflammatory conditions, in particular inflammatory conditions with an aetiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases, has been intensive and reports and results in vitro, in animal models and in clinical trials are wide-spread in the literature. Specific auto-immune diseases for which cyclosporin therapy has been proposed or applied include, autoimmune hematological disorder (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, poly-chondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active

hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease) endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy).

[0005] Further areas of investigation have potential applicability as an anti-parasitic, in particular antiprotozoal agent, with possible uses suggested including treatment of malaria, coccidiomycosis and schistosomiasis and, yet more recently, use as an agent for reversing or abrogating anti-neoplastic agent resistance in tumours and the like.

[0006] A detailed write-up on the variety of naturally occurring and semi-synthetic cyclosporins, their classification, nomenclature etc. has already been published [c.f. Traber et al. 1, *Helv. Chim. Acta.* 60, 1247-1255 (1977); Traber et al. 2, *Helv. Chim. Acta.* (65 no. 162, 1655-1667 (1982); Kobel et al., *Europ. J. Applied Microbiology and Biotechnology* 14, 273-240 (1982); and von Wart-burg et al., *Progress in Allergy*, 38, 28-45 (1986)]. U.S. Pat. Nos. 4,108,985, 4,210,581 and 4,220,641; European Patent Publication Nos. 0 034 567 and 0 056 782; International Patent Publication No. WO 86/02080; Wenger 1, *Transp. Proc.* 15, Suppl. 1; 2230 (1983); Wenger 2, *Angew. Chem. Int. Ed.*, 24, 77 (1985); and Wenger 3, *Progress in Chemistry of Organic Natural Products* 50, 123 (1986). Among all the cyclosporins, cyclosporin A (also known as cyclosporine or cyclosporin) has established its utility in the area of organ transplant and therapy of autoimmune diseases.

[0007] Although cyclosporin is used most widely amongst all the immunosuppressants available so far, it suffers from a serious drawback of poor bioavailability.

[0008] The oral dosage forms existing lately in the market (i.e. those employing ethanol, olive oil as carrier medium in conjunction with Labrafil as surfactant (US patent no. 4,388,307) are unpleasant tasting galenic forms. The bioavailability levels using these dosage forms are low and exhibit wide inter-and intra-individual variations. Such dosage forms provide an average absolute bioavailability of ca 30%. Reported variation in bioavailability between subjects varies between a few percent for some patients to as much as 90% or more for others. Also a marked change in bioavailability for individuals with time is frequently observed.

[0009] Cyclosporin blood levels have to be maintained within a specified range to achieve the effective therapy. The required range varies according to the clinical status of the patient. Because of poor and variable bioavailability daily dosages need to achieve the desired blood levels need to be varied considerably in the existing dosage forms of cyclosporin and a concomitant monitoring of blood levels is essential. This adds an additional cost to be therapy.

[0010] In order to improve the bioavailability several attempts have been made to improve formulations of cyclosporin.

[0011] US patent no. 4,388,307 has proposed a method of preparation of drinks solution containing cyclosporin in a base of Labrafil, Miglyol, Ethanol, Corn/olive oil. However, such preparation suffered from the drawback that it can be presented only as a liquid for dilution in drinking water/fluid before use, otherwise it is very difficult to give an accurate dose. Bioavailability levels achieved using the systems is very low and exhibits wide variations between individuals, individual patient type and even for single individuals at different times during the course of therapy.

[0012] Han Gua Patent (Chinese Patent No. 94191895.5) explains the active compound of cyclosporin, fatty acid sugar ester and diluent carrier having good bioavailability. However, this compound suffers from the drawback that diluent degrades due to hygroscopicity of sugar ester and the stability is not of desired standards, (see also Pharmaceutical Research, Volume 6, No. 11, 1989, P958, "Solid Surfactant Solution of active Ingredients in Sugar Ester" and International Journal of Pharmaceutics, Vol. 92, 1993, P197, "Application of sucrose laurate a new pharmaceutical excipient, in Peroral formulation of cyclosporin A").

[0013] Chinese Patent 9419189.5 having equivalent EP 0702562 describes a powder dosage form of cyclosporin possessing comparatively higher stability and to some extent bioavailability when compared to the earlier formulations. This art describes adsorption of cyclosporin A with appropriate solvents on to a adsorbent along with a nonionic hydrophilic surfactant. The final product does not contain the solvent as this evaporates during the process of manufacturing. Thus this product does not suffer from the disadvantage arising out of solvent evaporation during shelf life and hence stability problems. The various pharmaceutical surfactants, polyhydric alcohols and solvents are well known to the art. The adsorbent used is Colloidal Silicon Dioxide. The blood level arising out of such product have been compared with the standard formulations as per US patent no. 4, 388, 307 with significant improvement in bioavailability. However, if compared with the micro-emulsion based formulations these formulations do not show any advantage as the drug is adsorbed on solid surface and needs an additional process of dissolution prior to become bioavailable.

[0014] The effect of sucrose laurate on the gastrointestinal absorption of cyclosporine is also described (Lerk-PC; Sucker-H, International Journal of Pharmaceutics; 1993; 92; (May 3); 197-202). The evaluation of the dosage form containing sucrose Laurate was found to enhance the in vitro absorption of cyclosporine when normal epithelial tissue and Peyer's patch tissue of guinea pigs were used. Compared to the commercially available drinking solution, absorption was raised by a factor of 10. Excess amount of surfactant reduced drug absorption. Despite large excess of Sucrose laurate, the absorption of cyclosporin was still superior to the drinking solution. Choleic acid was also found to increase

absorption by a factor of 5-6. A comparison of the absorption between normal epithelial and Peyer's patch tissues indicated that the absorption by endocytosis does not contribute significantly to the overall absorption of cyclosporin. It was concluded that preliminary formulation experiments showed that a solid oral dosage form of cyclosporin could be made using sucrose laurate as an excipient.

5 **[0015]** Abdallah-HY; Mayersohn-M. Pharmaceutical Research; 1991;8 (Apr);518-522 reported several formulations of cyclosporin were prepared and examined in vitro and in dogs. A tablet formulation was then selected for comparison with the commercial oil solution placed in a soft gelatin capsule in a randomized crossover study in dogs. Compared with an intravenous dose of the drug, absolute bioavailability was 46±11.1 and 45±9.9% for the capsules and tablets, respectively. Maximum concentration, time to reach maximum concentration and mean absorption time were not significantly different between the 2 formulations. It was concluded that the tablet formulation of cyclosporin is equivalent in dogs to the commercial dosage form packed into soft gelatin capsules.

**[0016]** US patent no. 5051402 describes that cyclosporin may be rendered more soluble by the concomitant administration of  $\alpha$ -Cyclodextrin, either separately, but essentially simultaneously or, preferably, in admixture.

10 **[0017]** US Patent No. 4990337 describes a formulation comprising a cyclosporin in admixture with at least one mono or diglyceride of a C<sub>6</sub>-C<sub>10</sub> fatty acid sufficient to dissolve the cyclosporin. The resulting solution can then easily be emulsified in water or an aqueous fluid.

**[0018]** Freeze dried liposome mixture containing cyclosporin has been described in US Patent no. 4963362. This invention provides a freeze-dried potential liposome mixture having an amphipathic lipid and a cyclosporin or derivative thereof for use in possible liposome delivery of cyclosporin into cells. A method to produce the freeze-dried mixture is also disclosed. When reconstituted to yield liposomes in an aqueous medium, substantially all of the cyclosporin present in the freeze-dried mixture is encapsulated in the liposomes.

20 **[0019]** Other galenic improvements in cyclosporin emulsion formulations recorded in prior art are the use of tocopherol derivatives (EP 0724452), tocopheryl polyethylene glycol carboxylic acid ester (EP 0712631), dimethylisorbide (EP 0711550, EP 0650721), alkylene polyether or polyester (WO 9423733), emulsion compositions (EP 0694308), anhydromannitol oleylether, lactoglyceride, citroglycerides (EP 656212), phosphatidyl ethanolamine (EP 0651995), as surfactants and stabilizers etc.

25 **[0020]** Three Patent Applications namely European Patent App. No. 94110184.2, 95117171.9 and PCT/EP95/04187 describe the use of Dimethylisorbide as a co-surfactant or a hydrophilic phase along with other ingredients to enhance the absorption of cyclosporin.

30 **[0021]** One of the most significant attempt to improve bioavailability of cyclosporin from its dosage form is the described in US patent no. 5,342,625. This art describes use of microemulsion pre-concentrate consisting of a three phase systems i.e. (1) a hydrophilic phase component (2) a lipophilic phase component and (3) a surfactant. Such composition has alcohol as an essential ingredient, such composition upon dilution with water provides an oil-in-water microemulsion with an average particle size of less than 1000Å. Such an enhanced surface area results in increased bioavailability of cyclosporin when compared with conventional dosage forms. A comparison of bioavailability from micro-emulsion dosage form (Composition I from US patent no. 5,342,625) with the conventional ethanol-oil based dosage form (composition from US patent no. 5,342,625), earlier reported in US patent no. 4,388,307) has been performed in healthy human volunteers and reported in US patent no. 5,342,625. Bioavailability level of 149.0% (±48) is recorded for composition I as compared to composition X (for which bioavailability achieved is set as 100%). The mean AUC levels from composition I were 40% higher when compared to those from composition X but still had a high variation of 20%.

40 **[0022]** Alcohol is an essential part of composition as is evident from the products available in the market (Sandimun [US Pat. No. 4,388,307] and Neoral [US Pat. No. 5,342,625]) both of which contain Alcohol. Such compositions suffer from severe drawback of instability due to evaporation of a low boiling solvent like Alcohol. This is particularly true as the products are used in home environment, which cannot be precisely controlled with respect to temperature. Although very expensive cumbersome technology (such as cold formed Aluminium/ Aluminium Blister packs) is adopted to protect these products, yet the problem of instability is not completely solved. The stability problems are evident from strict storage conditions and usage requirements as declared either on the labels or package inserts of commercial products Sandimun, and Neoral drink solutions and capsules. Some of the examples are:

50 1. There is a requirement of storage of product below 30°C at the same time refrigeration is prohibited. This means that a patient using this product in a tropical country need to have an air-conditioned home environment. This is not only a limiting factor in use of this product but sometimes in economically backward countries it may not be possible that every person using the product has an air-conditioned storage area. Sometimes factors like prolong electricity failure and mechanical and electrical defects in air-conditioning system can cause instability problems to these products rendering them unstable for use.

55 2. There is also an a statement in Packing insert of Sandimun and Neoral drink solutions that "Sandimun Neoral solution should be used within 2 months of opening the bottle and be stored between 15° and 30°C, preferably

not below 20°C for prolonged periods, as it contains oily components of natural origin which tend to solidify at low temperatures. A jelly-like formation may occur below 20°C, which is however reversible at temperatures up to 30°C. Minor flakes or a slight sediment may still be observed. These phenomena do not affect the efficacy and safety of the product, and the dosing by means of the pipette remains accurate." indicating instability problems.

**[0023]** US Patent no. 5,639,724 discloses pharmaceutical compositions comprising cyclosporin, transesterification product of a natural vegetable oil with glycerol which is exemplified in the specification as MAISIN (transesterification product of corn oil and glycerol) which is an essential feature of the compositions. This composition necessitates that cyclosporin be mixed with a transesterification product of a natural vegetable oil with glycerol. Such composition is not fit for drink solution because of formation of jelly like lumps, since the transesterification product is a jelly like substance at room temperature. Such composition also preferably uses alcohol. This compositions compares its bioavailability with that of older and inferior compositions based on US patent no. 4, 388, 307 and does not compare bioavailability with a more recent a marketed compositions (NEORAL) as defined in US patent no. 5,342,625.

**[0024]** The formulation of emulsion as well as microemulsion present their own technological problems relating to thermodynamic instability. Such problems may be partially solved by presenting the product in a microemulsion pre-concentrate form wherein the microemulsification occurs in vivo only. However, such systems may also present variability problems due to wide variations existing in GI tract of patients.

**[0025]** Any person skilled in the art attempting to make composition without use of alcohol and without careful and extensive experimentation and study of desired chemicals to be added to cyclosporin will end with compositions which are highly viscous and which tend to solidify at normal room temperature conditions. Such compositions are undesirable not only due to physical unstability but also that they cannot be formulated as liquids whose dose can be measured exactly under normal conditions.

**[0026]** The major consideration here is the accurate measurement of dose in cyclosporin which is an essential feature because of the narrow therapeutic condition of the drug i.e. below threshold the organ rejection occurs and above a particular level the drug causes severe toxic reactions.

**[0027]** None of the above mentioned inventions teaches the art of dissolving cyclosporin A (which is a water insoluble hydrophobic drug) in a hydrophilic medium. This looks improbable and a person skilled in the art cannot conceive beyond an emulsion and/or a microemulsion.

**[0028]** All the earlier approaches to enhance the bioavailability of cyclosporin were towards making the drug in a emulsified form (US Patent no. 4,388,307) or substantially increasing the surface area by converting into microemulsion (US Patent No. 5,342,625).

**[0029]** MASINE is a fatty material which gets out not only when combined with cyclosporin but even when combined with Labrafil along with cyclosporin.

**[0030]** In the body of the specification of US Patent No. 5,639,724 Labrafil has been disclosed as a preferred ingredient to be added to the composition of cyclosporin and MAISINE for drink solution. However, this patent does not address the problem of formation of flake like substances formed by the presence of MAISINE even though Labrafil has been added to the composition.

**[0031]** Our attempt has been to affect solution of cyclosporin in a hydrophilic environment using micellar concept of a surfactant and a co-surfactant such that such compositions are substantially devoid of fatty materials and hence also devoid of the defects associated with such fatty materials. Our composition when diluted with water or aqueous medium retains the lipophilic cyclosporin drug in a solubilized state. Hence making the drug bioavailable in therapeutic concentrations and with reproducibility.

**[0032]** It will be most appropriate to formulate cyclosporin compositions in a way that the drug gets converted into a solubilized system on dilution in vivo. The compositions of the invention when administered orally in the form of a drink solution or soft gelatin capsules are diluted with the gastrointestinal fluids to form micellar solutions such that the hydrophilic end of the surfactant and the cosurfactant are oriented towards hydrophilic environment of gastrointestinal fluid and the drug molecules are entrapped in the hydrophobic portions of the surfactant micelles. Such micellar solubilized systems, when in contact with the mucosa of the gastrointestinal tract, release the drug leading to absorption, thus providing an increased and less variable bioavailability.

**[0033]** Such systems will definitely be more uniform and bioavailable than microemulsions from where the drug has to partition out of lipophilic phase for absorption.

**[0034]** Moreover, the inventors have done a detailed study of the type of products developed out of the technology based on microemulsion based systems.

**[0035]** The product existing in the commercial market are presented into two types of oral dosage forms.

**[0036]** One type is the oral solution concentrates to be diluted prior to intake as start up therapies. These dosage forms provide more flexibility in dosage adjustments to achieve the optimum therapeutic concentrations as desired by the physicians.

**[0037]** The second type of dosage forms are unit dosage forms for example capsules generally soft gelatin capsules.

These type of dosage forms are used as continuation therapies once the dosage adjustments have been done.

[0038] The inventors have, by careful experimentation and expenditure of mental faculties been able to invent a composition in which hydrophobic drug like cyclosporin can be dissolved in a hydrophilic medium by careful selection of the hydrophilic medium, surfactants and manner of addition such that a hydrophobic drug can get dissolved in an array of surfactant molecules arranged in a manner that their hydrophilic portions are oriented outside i.e. towards the hydrophilic medium resulting in clear stable solutions based formulations. Such products when they come in contact with biological fluids result in total solubilization of cyclosporin at molecular levels thereby increasing the surface area of cyclosporin and such diluted solutions of cyclosporin are highly bioavailable. Such compositions do not form emulsions on dilution.

[0039] In another embodiment of the invention there is disclosed an improved process for making soft gelatin capsules containing cyclosporin as active ingredient in a "carrier medium" comprising propylene glycol, a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol such as apricot kernel oil polyethylene glycol 6 esters such as Labrafil M 1944, poloxyethylene hydrogenated castor oils such as Cremophor RH 40 and glycerol triacetate or triacetin wherein the ingredients are present in the following range:

Cyclosporin	1-25 %w/w
Propylene glycol	10-50% w/w
A transesterification product of a natural vegetable oil triglyceride and : a polyalkylene polyol	5-30% w/w
Polyoxyethylene hydrogenated castor oils	30-60% w/w
Triacetin	0.1-30% w/w

[0040] Such dosage forms that is soft gelatin capsules pose unique technology problems when the solutions to be encapsulated are microemulsion preconcentrates. There is a tendency to loose weight due to the migration of materials with free hydroxy groups into the capsule shell thus causing precipitation of drug due to loss of solvent.

[0041] In the present invention this problem has been solved by adding to the said composition of the invention substantially 10-25% excess of the "carrier medium" thereby compensating for the loss of weight due to migration. At the same time the amount of plasticizers in the capsule shell are reduced by the amount equivalent to the excess carrier medium added in the capsule.

[0042] The terms "base" or "carrier medium" should be implied to mean everything added to the composition except the drug.

[0043] The composition is incorporated into the capsule shell by conventional procedures as described in standard texts. ( "The theory and practice of Industrial Pharmacy" by Leon Lachman et al. Third edition, LEA AND FEBIGER, USA )

[0044] The soft gelatin capsules have a very distinct advantage of ease of carrying and administration as compared with oral solutions. These dosage forms hence contribute to a very large segment of commercial market.

[0045] The present invention relates to formulation of cyclosporin in compositions such that the drug is presented in solubilized systems of surfactant micelles appropriately stabilised in specific hydrophilic phase.

#### SUMMARY OF THE INVENTION

[0046] In accordance with the present invention there is described a homogeneous substantially alcohol free, transparent solution of a cyclosporin which is clear, stable, flowable and easily measurable at a temperature of 15° to 45°C, which comprises a solution of a cyclosporin in a hydrophilic carrier medium comprising (1) propylene glycol, (2) a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol, (3) a polyoxyethylene hydrogenated castor oil product and (4) triacetin.

[0047] The ingredients are generally present in the following ranges:

Cyclosporin	1-25% w/w
Propylene glycol	10-50% w/w
A transesterification product of a natural: vegetable oil triglyceride and a polyalkylene polyol.	5-30% w/w
Polyoxyethylene hydrogenated Castor oils	30-60% w/w
Triacetin	0.1-30% w/w

[0048] Preferably the ingredients in the present compositions are present in the following ranges:

Cyclosporin	5-15% w/w
-------------	-----------

(continued)

Propylene Glycol	15-45% w/w
A transesterification product of a natural: vegetable oil triglyceride and a polyalkylene polyol.	7-20% w/w
Polyoxyethylene hydrogenated Castor oils	35-55% w/w
Triacetin	1-10% w/w

[0049] More preferably the composition in accordance with the present invention comprises the ingredients in the following ranges:

Cyclosporin	8-12% w/w
Propylene Glycol	20-40% w/w
A transesterification product of a natural: vegetable oil triglyceride and a polyalkylene polyol.	10-15% w/w
Polyoxyethylene hydrogenated Castor oils	40-50% w/w
Triacetin	2-5% w/w

#### DETAILED DESCRIPTION OF THE INVENTION

[0050] The systems of the present invention are single phase systems in contrast to emulsion/microemulsions wherein an essentially lipophilic phase is emulsified or microemulsified with a hydrophilic phase using a surfactant.

[0051] The expression "single phase" means a phase wherein the drug is solubilised in hydrophilic phase using suitable surfactant(s)/ co-surfactant(s). A separate lipophilic phase is not present.

[0052] The compositions in this invention are substantially free of ethanol.

[0053] It is most beneficial in context of hot tropical countries where absence of C<sub>1-5</sub> alkanols such as ethanol are more due to evaporation.

[0054] Such compositions of the present invention which are solubilized systems and substantially free of C<sub>1-5</sub> alkanols such as ethanol are distinctly advantageous over the ones described in US patent no. 5,342,625 with respect to manufacturing and distribution in the tropical countries.

[0055] In accordance with the present invention there is described a homogenous substantially alcohol free, transparent composition of cyclosporin which is clear, stable, flowable and easily measurable at a wide range of temperature of 15° to 45°C which comprises a cyclosporin in a hydrophilic carrier medium comprising propylene glycol, a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol, polyoxyethylene hydrogenated castor oils and glycerol triacetate or triacetin wherein the ingredients are present in the following ranges:

Cyclosporin	1-25% w/w
Propylene Glycol	10-50% w/w
A transesterification product of a natural: vegetable oil triglyceride and a polyalkylene polyol.	5-30% w/w
Polyoxyethylene hydrogenated Castor oils	30-60% w/w
Triacetin	0.1-30% w/w

[0056] Preferably such compositions further comprises oleic acid. Such oleic acid may be present in the range 0-10% w/w.

[0057] Preferably the transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol is apricot kernel oil polyethylene glycol 6 esters. More preferably the apricot kernel oil polyethylene glycol 6 ester is Labrafil M1944.

[0058] Preferably the polyoxyethylene hydrogenated castor oil is polyoxyethylene 40 hydrogenated castor oil. Especially suitable is product available under the trade name Cremophor RH 40.

[0059] Preferably the ingredients in the present compositions are present in the following ranges:

Cyclosporin	5-15% w/w
Propylene Glycol	15-45% w/w
A transesterification product of a natural: vegetable oil triglyceride and a polyalkylene polyol.	7- 20% w/w
Polyoxyethylene hydrogenated Castor oils	35-55% w/w
Triacetin	1-10% w/w

[0060] More preferably the composition in accordance with the present invention comprises the ingredients in the following ranges:

Cyclosporin	8-12% w/w
Propylene Glycol	20-40% w/w
A transesterification product of a natural: vegetable oil triglyceride and a polyalkylene polyol.	10- 15% w/w
Polyoxyethylene hydrogenated Castor oils	40-50% w/w
Triacetin	2-5% w/w

[0061] Very small amounts of antioxidants usually in the range of 0.005% to 0.01% w/w may be present as ingredients of the composition.

[0062] The amount of the ingredients of the composition disclosed above equals to 100%.

[0063] The formulation can be prepared so as to be diluted as a drink solution or incorporated into soft gelatin capsules.

[0064] The term "easily measurable" has been used due to the characteristic features of the drug cyclosporin. Cyclosporin requires accurate dose measurement because of its narrow therapeutic index. Most of the drink solution packs are provided with a pipette or a syringe for accurate dose measurement. This warrants that the solution is a sufficiently thin liquid to permit ease of measurement and not a semi solid mass and also it should be devoid of any flakes, jelly like formations or other sediments which can cause non-homogeneity in the dose. The composition of our invention possesses all the desired characteristics and hence is easily measurable as far as the dose requirements is concerned.

[0065] Several compositions as per this invention with different ranges of ingredients were subjected to commercial production trials and shelf-life stability studies and the inventors were successful in arriving at a composition which was easy to manufacture and stable for long periods of time when tested by accelerated stability studies.

[0066] Moreover when tested on healthy human volunteers, the composition(s) of this invention were found to have excellent bioavailability of cyclosporin and were also found to be bioequivalent with commercial products. The comparative results are collected in Table I & II.

[0067] The invention will now be described with reference to the accompanying examples which should not be construed to limit the scope of the invention:

#### EXAMPLE 1 (PRIOR ART)

[0068]

	COMPONENT	AMOUNT
a)	Cyclosporin	100 mg (= ca. 10.5%)
b)	Maisine	550 mg (= ca. 57.8%)
c)	Labrafil M 2125	300 mg (= ca. 33.5%)
	TOTAL	950 mg

[0069] The mixture obtained was a semi-solid mass at room temperature suitable only for soft gelatin capsule formulation.

#### EXAMPLE 2 (PRIOR ART)

[0070]

	COMPONENT	AMOUNT
a)	Cyclosporin	100 mg (= ca. 10.5%)
b)	Maisine	490 mg (= ca. 52%)
c)	Labrafil M 2125	300 mg (= ca. 31.5%)
d)	Crémophor RH40	60 mg (= ca. 6.3%)
	TOTAL	950 mg



[0071] The mixture obtained was a semi-solid mass at room temperature suitable only for soft gelatin capsule formulation.

### EXAMPLE 3 (PRIOR ART)

[0072]

	COMPONENT	AMOUNT
a)	Cyclosporin	100 mg (= ca. 10.5%)
b)	Maisine	850 mg (= ca. 52%)
	TOTAL	950 mg

[0073] The mixture obtained was a semi-solid mass at room temperature suitable only for soft gelatin capsule formulation.

### EXAMPLE 4 (PRIOR ART)

[0074]

	COMPONENT	AMOUNT
a)	Cyclosporin	100 mg
b)	Propylene Glycol	200 mg
c)	Cremophor RH40	350 mg
d)	Labrafil M1944	200 mg
e)	Maisine	150 mg
	TOTAL	1000 mg

[0075] The composition obtained was a clear, homogenous liquid at a temperatures between 25° to 30°C, but at temperatures below 20°C jelly like flakes separated out.

### EXAMPLE 5

[0076]

	COMPONENT	AMOUNT
a)	Cyclosporin	200 mg
b)	Propylene Glycol	240 mg
c)	Cremophor RH40	430 mg
d)	Labrafil M1944	110 mg
e)	Triacetin	20 mg
	TOTAL	1000 mg

[0077] Above composition gives a clear, homogeneous solution which remains clear and stable at temperatures between 15° to 45°C without any jelly like flake formation. Hence this composition is suitable for formulating as a drink solution or soft gelatin capsules.

[0078] Propylene glycol was mixed with Cremophor RH 40 and heated upto 55 to 60 °C. Cyclosporin was dissolved in the resultant mixture. Labrafil M1944 was added to the bulk and mixed. Triacetin was then added to the bulk mixture and mixed. The resultant mixture was then filtered.

**EXAMPLE 6****[0079]**

	COMPONENT	AMOUNT
a)	Cyclosporin	200 mg
b)	Propylene Glycol	257 mg
c)	Cremophor RH40	425 mg
d)	Labrafil M1944	100 mg
e)	Triacetin	18 mg
	TOTAL	1000 mg

**[0080]** Above composition gives a clear, homogeneous solution which remains clear and stable at temperatures between 15° to 45°C without any jelly like flake formation. Hence this composition is suitable for formulating as a drink solution or soft gelatin capsules.

**[0081]** Propylene glycol was mixed with Cremophor RH 40 and heated upto 55 to 60 °C. Cyclosporin was dissolved in the resultant mixture. Labrafil M1944 was added to the bulk and mixed. Triacetin was then added to the bulk mixture and mixed. The resultant mixture was then filtered.

**EXAMPLE 7****[0082]**

	COMPONENT	AMOUNT
a)	Cyclosporin	150 mg
b)	Propylene Glycol	260 mg
c)	Cremophor RH40	460 mg
d)	Labrafil M1944	110 mg
e)	Triacetin	20 mg
	TOTAL	1000 mg

**[0083]** Above composition gives a clear, homogeneous solution which remains clear and stable at temperatures between 15° to 45°C without any jelly like flake formation. Hence this composition is suitable for formulating as a drink solution or soft gelatin capsules.

**[0084]** Propylene glycol was mixed with Cremophor RH 40 and heated upto 55 to 60 °C. Cyclosporin was dissolved in the resultant mixture. Labrafil M1944 was added to the bulk and mixed. Triacetin was then added to the bulk mixture and mixed. The resultant mixture was then filtered.

**EXAMPLE 8****[0085]**

	COMPONENT	AMOUNT
a)	Cyclosporin	50 mg
b)	Propylene Glycol	350 mg
c)	Cremophor RH40	420 mg
d)	Labrafil M1944	110 mg
e)	Triacetin	20 mg
f)	Oleic Acid	50 mg
	TOTAL	1000 mg

**[0086]** Above composition gives a clear, homogeneous solution which remains clear and stable at temperatures between 15° to 45°C without any jelly like flake formation.

**[0087]** Hence this composition is suitable for formulating as a drink solution or soft gelatin capsules.

[0088] Propylene glycol was mixed with Cremophor RH 40 and heated to 55 to 60 °C. Cyclosporin was dissolved in the resultant mixture. Labrafil M1944 and oleic acid were then added to the bulk and mixed. Triacetin was then added to the bulk mixture and mixed. The resultant mixture was then filtered.

#### EXAMPLE 9

[0089]

	COMPONENT	AMOUNT
a)	Cyclosporin	10 mg
b)	Propylene Glycol	400 mg
c)	Cremophor RH40	420 mg
d)	Labrafil M1944	150 mg
e)	Triacetin	20 mg
	TOTAL	1000 mg

[0090] Above composition gives a clear, homogeneous solution which remains clear and stable at temperatures between 15° to 45°C without any jelly like flake formation. Hence this composition is suitable for formulating as a drink solution or soft gelatin capsules.

[0091] Propylene glycol was heated to 55 to 60°C and Cyclosporin was dissolved therein. Cremophor RH 40 was added to the bulk and mixed. Labrafil M1944 was added to the bulk and mixed. Triacetin was then added to the bulk mixture and mixed. The resultant mixture was then filtered.

#### EXAMPLE 10

[0092]

	COMPONENT	AMOUNT
a)	Cyclosporin	100 mg
b)	Propylene Glycol	240 mg
c)	Cremophor RH40	480 mg
d)	Labrafil M1944	160 mg
d)	Triacetin	20 mg
	TOTAL	1000 mg

[0093] Propylene glycol was mixed with Cremophor RH 40 and heated upto 55 to 60°C and Cyclosporin was dissolved in the resultant. Labrafil M1944 was added to the bulk and mixed. Triacetin was then added to the bulk mixture and mixed. The resultant mixture was then filtered.

#### Example 11

##### Process for making Soft Gelatin Capsules of Cyclosporin

[0094] The compositions as mentioned in the prior art suffer from a disadvantage of migration of carrier medium comprising solvents containing free -OH groups particularly ethanol into the shell leading to precipitation of drug in the capsules. If alcohol is removed it also leads to precipitation of drug.

[0095] To overcome this problem we have surprisingly found in the composition of the present invention that by increasing the amount of carrier medium in the core composition by about 20% at the time of encapsulation and reducing the amount of plasticizers (sorbitol and glycerin) in the capsule shell composition by 20% yields soft gelatin capsules which on storage attain equilibrium and remain stable throughout the shelf life as exemplified below:

Batch size : 100,000 capsules

Core Composition	
a) Cyclosporin	5 kg

(continued)

Core Composition		
b)	Carrier Medium*	55 kg
	*Includes 20% extra carrier medium Composition of carrier medium	
i)	Propylene Glycol	10.8 kg
ii)	Cremophore RH40	24.9 kg
iii)	Labrafil M1944	18.1 kg
iv)	Triacetin	1.2 kg

Capsule shell composition		
i)	Gelatin	50 kg
ii)	Sorbitol	8 kg
iii)	Glycerine	8 kg
iv)	Methyl Paraben	240 g
v)	Propyl Paraben	140 g
vi)	Water	45 kg
vii)	Colour	400 g

Table I

Plasma Concentration Of Cyclosporin (ng/ml) Following Administration Of a Single Oral Dose Of 2.5 mg/kg Body Wt. Cyclosporin														
Name of the preparation : Cyclosporin Composition as per Example 10														
Cyclosporin Plasma Concentration (ng/ml)														
Volunteers														
Time (Hrs.)	1	2	3	4	5	6	7	8	9	10	11	12	Mean	S.D
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	507.02	524.93	318.14	339.72	484.29	284.79	495.09	323.50	233.15	545.52	121.57	318.47	374.50	128.58
2	976.15	685.17	676.67	879.30	509.18	330.00	540.17	468.40	670.99	1050.17	496.62	572.56	654.82	207.75
2	767.23	720.42	752.85	834.18	493.70	358.80	496.83	440.80	741.30	864.68	751.07	513.84	644.59	163.99
3	583.14	529.36	582.94	984.11	651.30	388.54	622.55	314.57	652.49	616.40	468.99	438.30	569.31	162.64
3	440.50	532.52	338.03	957.49	950.12	493.15	610.79	241.05	439.72	579.65	340.29	418.09	528.03	215.19
4	344.75	310.85	209.30	425.88	390.23	152.59	456.25	170.91	342.17	340.47	252.28	110.21	292.16	107.28
6	166.74	183.19	110.32	376.34	213.65	56.52	244.53	125.10	113.28	112.57	194.69	59.42	163.02	85.36
9	108.50	118.21	86.91	112.71	84.05	38.23	81.58	64.45	73.72	89.42	112.75	41.64	84.35	25.61
12	106.23	119.25	32.17	75.07	67.94	29.83	45.21	38.21	29.34	50.80	46.11	33.86	56.21	28.89
24	42.38	7.36	4.53	10.21	3.20	0.00	0.00	13.82	0.00	0.00	0.00	0.00	6.80	11.63

Cmax (ng/ml)	976.15	720.42	752.85	984.11	950.12	493.15	622.55	468.54	741.30	1050.17	751.07	572.56	654.82	215.19
Tmax (hrs.)	2.00	2.50	2.50	3.00	3.00	3.50	3.00	2.00	2.50	2.00	2.50	2.00	2.54	0.48
AUC (0-24)	3459.60	3185.80	2543.80	4709.40	3656.3	1717.90	3510.30	2130.60	2769.1	3294.90	2624.30	1886.10	3024.80	1211.20

Table II

Plasma Concentration Of Cyclosporin (ng/ml) Following Administration Of A Single Oral Dose Of 2.5 mg/kg Body Wt. Cyclosporin													
Name of the preparation : SANDIMUN NEORAL													
Cyclosporin Plasma Concentration (ng/ml)													
Volunteers													
Time (Hrs.)	1	2	3	4	5	6	7	8	9	10	11	12	S.D
0	19.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1	563.04	618.39	553.99	301.79	124.87	136.60	382.63	406.81	317.83	284.23	312.92	162.22	347.21
2	973.61	688.13	695.99	573.50	252.43	234.67	600.86	545.81	572.20	608.90	1005.59	609.00	813.35
2	799.31	-	815.39	849.32	222.23	225.39	283.25	581.01	550.87	1113.49	976.24	629.66	586.76
3	871.51	848.54	564.36	654.42	292.19	147.92	292.86	395.61	389.28	958.44	1174.33	784.34	593.24
3	663.07	381.19	785.13	658.20	83.34	96.44	180.02	337.68	287.32	650.95	-	476.92	403.35
4	479.11	508.23	203.31	220.43	126.02	155.19	167.99	258.38	131.69	374.63	413.61	390.79	301.70
6	244.93	219.30	150.01	315.89	54.23	100.41	155.89	155.50	73.56	209.46	198.43	236.47	176.01
9	173.89	239.76	138.19	187.56	45.03	30.44	213.96	61.45	46.26	135.34	114.97	98.98	119.47
12	89.20	185.38	-	129.76	-	19.41	76.61	94.40	-	-	12.82	20.46	54.01
24	23.92	55.17	0.00	0.00	0.00	54.73	53.43	11.40	0.00	0.00	0.00	0.00	16.55
													24.05

Cmax (ng/ml)	973.61	688.13	815.39	849.32	291.19	234.67	600.86	581.01	572.2	1113.49	1174.33	784.34	723.21	278.57
Tmax (hrs.)	2.50	2.00	2.00	2.00	2.50	2.00	2.00	2.00	2.00	2.00	3.00	2.50	2.20	0.40
AUC (0-24)	4887.00	5394.20	3136.60	4805.00	1000.4	1527.80	2889.20	3056.50	1730.20	3533.40	3364.80	3118.60	3203.6	1364.0

## Claims

1. A homogeneous substantially alcohol free, transparent solution of a cyclosporin which is clear, stable, flowable and easily measurable at a temperature of 15° to 45°C, which comprises a solution of a cyclosporin in a hydrophilic carrier medium comprising (1) propylene glycol, (2) a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol, (3) a polyoxyethylene hydrogenated castor oil product and (4) triacetin.

2. A composition as claimed in claim 1 wherein the ingredients are present in the following ranges:

Cyclosporin	1-25% w/w
Propylene Glycol	10-50% w/w
A transesterification product of a natural vegetable oil : triglyceride and a polyalkylene polyol.	5-30% w/w
Polyoxyethylene hydrogenated Castor oils	30-60% w/w
Triacetin	0.1-30% w/w

3. A composition as claimed in claim 1 wherein the ingredients are present in the following ranges:

Cyclosporin	5-15% w/w
Propylene Glycol	15-45% w/w
a transesterification product of a natural vegetable oil : triglyceride and a polyalkylene polyol.	7-20% w/w
Polyoxyethylene hydrogenated Castor oils	35-55% w/w
Triacetin	1-10% w/w

4. A composition as claimed in claim 1 wherein the ingredients are present in the following ranges:

Cyclosporin	8-12% w/w
Propylene glycol	20-40% w/w
A transesterification product of a natural vegetable oil : triglyceride and a polyalkylene polyol	10-15% w/w
Polyoxyethylene hydrogenated castor oils	40-50% w/w
Triacetin	2-5% w/w

5. A composition as claimed in any preceding claim which on dilution with aqueous media yields solution of cyclosporin thus favourably affecting absorption.

6. A composition claimed in any preceding claim which is used as a drink solution.

7. A composition as claimed in any of claims 1 to 4 presented in soft gelatin capsules.

8. A composition as claimed in any preceding claim which further comprises oleic acid.

9. A composition as claimed in claim 8 wherein oleic acid is present in the range from 0-10% w/w.

10. An improved process for making soft gelatin capsules as claimed in claim 7 which comprises adding to the said composition substantially 10-25% excess of the base carrier medium thereby compensating for the loss of weight due to migration of free hydroxy groups with the capsule shell thus preventing precipitation of drug due to loss of solvent and reducing substantially 10-25% of the polyols such as sorbitol and glycerol which are used as plastisizers from the capsule shell.



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 98 30 6607 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,X	US 5 639 724 A (CAVANAK THOMAS) 17 June 1997 * column 22; examples 2,3 *	1-10	A61K38/13 A61K9/48 A61K9/107 A61K9/10
A	WO 97 04795 A (POLI IND CHIMICA SPA ;SHANKS ANDREW (GB); POLI STEFANO (IT); BUSET) 13 February 1997 * claim 7 *	1-10	
A	EP 0 649 651 A (SCHERER GMBH R P ;SANDOZ AG (CH)) 26 April 1995 * page 7; example 2 *	1-10	
A	EP 0 539 319 A (SANDOZ LTD) 28 April 1993 * page 8; example 2 *	1-10	
A	FR 2 636 534 A (SANDOZ SA) 23 March 1990 * page 27, line 4 - line 5 * * page 59; example 1.6 *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		21 January 1999	Boulois, D
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C07)





European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number  
EP 98 30 6607

The expression "substantially alcohol free" in Claim 1 present is inconsistent with the presence of alcoholic compounds like propylene glycol ( Article 84 EPC ).  
The search has been directed to compositions without any alcohol compound, apart from the compounds claimed in claim 1.

# ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 98 30 6607

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-01-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5639724 A	17-06-1997	US 5759997 A	02-06-1998
		US 5652212 A	29-07-1997
		BE 1005236 A	08-06-1993
		CH 680650 A	15-10-1992
		CY 1886 A	05-04-1996
		DE 4005190 A	23-08-1990
		FR 2643262 A	24-08-1990
		GB 2228198 A, B	22-08-1990
		HK 149595 A	29-09-1995
		IT 1240765 B	17-12-1993
		JP 1888154 C	07-12-1994
		JP 2255623 A	16-10-1990
		JP 6011703 B	16-02-1994
WO 9704795 A	13-02-1997	IT MI951610 A	27-01-1997
		AU 6528596 A	26-02-1997
EP 0649651 A	26-04-1995	AU 690571 B	30-04-1998
		AU 7423794 A	13-04-1995
		AU 7511298 A	01-10-1998
		CA 2132933 A	29-03-1995
		CN 1108930 A	27-09-1995
		CZ 9402360 A	12-04-1995
		FI 944452 A	29-03-1995
		FR 2710532 A	07-04-1995
		GB 2282586 A, B	12-04-1995
		GB 2317155 A, B	18-03-1998
		HU 70417 A	30-10-1995
		IT RM940613 A, B	28-03-1995
		JP 7149625 A	13-06-1995
		NO 943563 A	29-03-1995
		NZ 264536 A	25-09-1996
		PL 305188 A	03-04-1995
		SG 46531 A	20-02-1998
		SK 115794 A	10-05-1995
		ZA 9407567 A	28-06-1996
EP 0539319 A	28-04-1993	AT 403436 B	25-02-1998
		AT 129892 A	15-07-1997
		AU 659460 B	18-05-1995
		AU 1852792 A	11-03-1993
		CA 2072509 A, C	28-12-1992
		CA 2175842 A	28-12-1992
		CH 684163 A	29-07-1994
		CH 685764 A	29-09-1995
		CZ 281790 B	15-01-1997

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 30 6607

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-01-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0539319 A		DE 4219526 A	18-03-1993
		FI 922958 A	28-12-1992
		FI 961513 A	03-04-1996
		FR 2678169 A	31-12-1992
		FR 2685706 A	02-07-1993
		GB 2257359 A,B	13-01-1993
		GB 2284615 A,B	14-06-1995
		HK 57196 A	12-04-1996
		HK 157696 A	30-08-1996
		IE 73662 B	18-06-1997
		IL 102310 A	18-03-1997
		IT 1254401 B	14-09-1995
		JP 2653958 B	17-09-1997
		JP 5186365 A	27-07-1993
		JP 9118894 A	06-05-1997
		LU 88138 A	01-03-1994
		MX 9203236 A	01-12-1992
		NO 303964 B	05-10-1998
		NO 964382 A	28-12-1992
		NZ 243309 A	24-02-1995
		SK 197792 A	09-03-1994
		ZA 9204719 A	27-12-1993
FR 2636534 A	23-03-1990	AT 403435 B	25-02-1998
		AT 214289 A	15-07-1997
		AU 627220 B	20-08-1992
		AU 4140089 A	22-03-1990
		BE 1003105 A	26-11-1991
		BG 60525 B	28-07-1995
		CA 1332150 A	27-09-1994
		CH 679118 A	31-12-1991
		CY 1711 A	06-05-1994
		DE 3930928 A	22-03-1990
		DK 171433 B	28-10-1996
		FI 894342 A,B,	17-03-1990
		GB 2222770 A,B	21-03-1990
		GR 89100583 A,B	31-10-1990
		HK 86593 A	27-08-1993
		HU 212727 B	28-10-1996
		HU 9500318 A	30-10-1995
		IE 60764 B	10-08-1994
		IL 91642 A	12-04-1994
		JP 1996397 C	08-12-1995
		JP 2121929 A	09-05-1990
		JP 7025690 B	22-03-1995
		LU 87586 A	07-05-1991

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 30 6607

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-01-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2636534 A		LV 5749 A	20-12-1996
		NL 8902315 A	17-04-1990
		NO 180362 B	30-12-1996
		PT 91731 A,B	30-03-1990
		SE 8903042 A	11-05-1990
		US 5741512 A	21-04-1998
		US 5342625 A	30-08-1994
<hr/>			

EPO FORM P0458

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82